Vistagen experienced a wider net loss in Q4 2025 compared to the previous year due to higher R&D and administrative expenses, as it advanced late-stage trials for key neuroscience therapies.

Vistagen reported a net loss of $14.1 million for the fiscal year 2025 third quarter, an increase from $6.4 million in the prior year. Research and development expenses significantly increased to $11.3 million, driven by advancements in its PALISADE Phase 3 Program and IND-enabling programs. The company also highlighted positive results from an exploratory Phase 2A trial of PH284 in cancer cachexia.

Vistagen reported a net loss of $13.0 million for the quarter ended September 30, 2024, compared to a net loss of $6.6 million for the same period in 2023. Research and development expenses increased to $10.2 million, and general and administrative expenses rose to $4.2 million. The company's cash, cash equivalents, and marketable securities totaled $97.6 million as of September 30, 2024.

Vistagen reported a net loss of $10.7 million for the first quarter of fiscal year 2025, with research and development expenses increasing to $7.6 million due to the PALISADE-3 trial and preparations for PALISADE-4. The company's cash, cash equivalents, and marketable securities totaled $108.4 million as of June 30, 2024.

Vistagen reported a net loss of $6.3 million for the third quarter of fiscal year 2024, with cash and cash equivalents of approximately $126.6 million as of December 31, 2023. The company is progressing with clinical trials for fasedienol, itruvone, and PH80.

Vistagen reported positive Phase 3 results for fasedienol and is preparing to initiate potential NDA-enabling Phase 3 studies in 2024. The company secured $137.7 million in gross proceeds since the beginning of the fiscal 2024 second quarter and has a strong financial position to fund operations through a potential fasedienol U.S. NDA submission.

Vistagen reported positive top-line results from the Phase 3 PALISADE-2 trial of fasedienol nasal spray in social anxiety disorder (SAD). The company is preparing for Phase 3 PALISADE-3 and FEARLESS trials. Net loss for the quarter was $6.9 million, with cash and cash equivalents at $9.6 million as of June 30, 2023.

Vistagen reported a net loss of $59.2 million for fiscal year 2023, with cash and cash equivalents of $16.6 million as of March 31, 2023. The company highlighted positive results from its Phase 3 open label study of fasedienol in social anxiety disorder and positive FDA feedback on the use of the LSAS as the primary efficacy endpoint in future Phase 3 studies.

Vistagen reported a net loss attributable to common stockholders of approximately $9.8 million for the fiscal quarter ended December 31, 2022. The company's cash and cash equivalents were approximately $25.0 million as of December 31, 2022. Vistagen completed the acquisition of Pherin Pharmaceuticals, securing full ownership of PH94B and PH10.

Vistagen reported a net loss of $17.5 million for the second quarter of fiscal year 2023, with cash and cash equivalents of $35.3 million at the end of the quarter. The company is preparing to restart the PALISADE-2 Phase 3 trial for PH94B in social anxiety disorder and plans to meet with the FDA regarding the next steps in Phase 3 development.

VistaGen Therapeutics reported its financial results for the first quarter of fiscal year 2023 ended June 30, 2022. The company is evaluating the results of PALISADE-1 and conducting an interim analysis of PALISADE-2. They anticipate a considerable reduction in external spending to conserve cash.

VistaGen Therapeutics reported its financial results for the fiscal year ended March 31, 2022. The company highlighted the completion of the last patient out milestone for the PALISADE-1 Phase 3 clinical trial of PH94B in social anxiety disorder and the anticipation of topline results, as well as the FDA's consensus that data from studies of PH94B provide no signal of abuse potential.

VistaGen Therapeutics reported its third quarter results, reflecting progress in advancing novel therapies for mental health disorders. The company is anticipating Phase 3 data for studies in the PALISADE program for PH94B in social anxiety disorder later this year and expanding clinical programs to explore opportunities in additional mental health conditions.

VistaGen Therapeutics reported a net loss of $12.8 million for the quarter ended September 30, 2021, compared to a net loss of $3.3 million for the same quarter in the previous year. The company's research and development expenses increased to $10.1 million, driven by the PALISADE Phase 3 Program for PH94B in SAD and the Phase 2A study of PH94B in AjDA. As of September 30, 2021, the company had cash and cash equivalents of approximately $93.6 million.

VistaGen Therapeutics reported financial results for its fiscal year 2022 first quarter ended June 30, 2021. The company recognized $0.4 million in sublicense revenue. Research and development expense increased by $3.9 million, and general and administrative expense increased to approximately $2.5 million. Net loss for the quarter was approximately $7.7 million. The Company had cash and cash equivalents of approximately $97.8 million at June 30, 2021.

VistaGen Therapeutics reported sublicense revenue of $1.1 million for the year ended March 31, 2021, stemming from their collaboration agreement with EverInsight Therapeutics. The company's cash and cash equivalents stood at approximately $103.1 million as of March 31, 2021. Net loss for the fiscal year was approximately $17.9 million.

VistaGen Therapeutics reported a decrease in net loss attributable to common stockholders to approximately $5.65 million, compared to $6.28 million for the same period in the previous year. The company recognized $313,600 in sublicense revenue, an increase from the previous year. Research and development expenses increased, while general and administrative expenses decreased. The company's cash and cash equivalents amounted to approximately $104.3 million at the end of the quarter.